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Summary of the article: We used publicly available data to assess the case fatality risk 
of COVID-19 in mainland China, stratified by region and clinical category. The case 
fatality risk was highest in Wuhan and increased with age, being male, and clinical 
severity.
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ABSTRACT 
Objective To assess the case fatality risk (CFR) of COVID-19 in mainland China, 
stratified by region and clinical category, and estimate key time-to-event 
intervals. 
Methods 
We collected individual information and aggregated data on COVID-19 cases 
from publicly available official sources from December 29, 2019 to April 17, 
2020. We accounted for right-censoring to estimate the CFR and explored the 
risk factors for mortality. We fitted Weibull, gamma, and lognormal distributions 
to time-to-event data using maximum-likelihood estimation. 
Results  
We analyzed 82,719 laboratory-confirmed cases reported in mainland China, 
including 4,632 deaths, and 77,029 discharges. The estimated CFR was 5.65% 
(95%CI: 5.50%-5.81%) nationally, with highest estimate in Wuhan (7.71%), and 
lowest in provinces outside Hubei (0.86%). The fatality risk among critical 
patients was 3.6 times that of all patients, and 0.8-10.3 fold higher than that of 
mild-to-severe patients. Older age (OR 1.14 per year; 95%CI: 1.11-1.16), and 
being male (OR 1.83; 95%CI: 1.10-3.04) were risk factors for mortality. The time 
from symptom onset to first healthcare consultation, time from symptom onset 
to laboratory confirmation, and time from symptom onset to hospitalization 
were consistently longer for deceased patients than for those who recovered. 
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Conclusions  
Our CFR estimates based on laboratory-confirmed cases ascertained in mainland 
China suggest that COVID-19 is more severe than the 2009 H1N1 influenza 
pandemic in hospitalized patients, particularly in Wuhan. Our study provides a 
comprehensive picture of the severity of the first wave of the pandemic in China. 
Our estimates can help inform models and the global response to COVID-19. 
 
KEY WORDS: Novel coronavirus diseases 2019, severe acute respiratory 
syndrome coronavirus 2, case fatality risk, China
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Introduction 
As of April 17, 2020, a total of 82,719 cases of novel coronavirus disease 2019 
(COVID-19) have been reported in mainland China, including 4,632 deaths [1, 2]. 
The first wave of COVID-19 transmission has ended in mainland China, due to 
implementation of stringent public health interventions [4]. However, as the 
pandemic continues throughout the world, China faces mounting pressure from 
travel-related case importations. As of April 17, a total of 1,566 imported cases 
were reported in 27 (87%, 27/31) Chinese provinces [1, 2]. Coupled with the 
decline of the public health response and resumption of economic activities, the 
risk of re-emergence of COVID-19 remains high [5]. 
 
The case fatality risk (CFR) is a key metric for clinical severity assessment. It is 
determined by multiple factors, including the intrinsic virulence of a pathogen, 
the availability of timely and appropriate treatment, the surge capacity of the 
healthcare system, and accessibility to medical care. Unbiased and precise 
estimates of CFR are important to help policy-makers balance the socioeconomic 
impact of interventions against the potential health benefits [6]. CFR is also a key 
parameter for mathematical models of SARS-CoV-2 transmission, which have 
been widely used throughout the outbreak to compare intervention scenarios.  
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Estimates of the fatality risk of COVID-19 in China have been highly variable 
(0.98%-18%) [5, 7-14] . These estimates addressed the early stages of the 
outbreak and suffer from censoring due to time delay between onset and death, 
they do not include recent updated in COVID-19 statistics [3], and they do not 
account for improved patient care in later stages of the outbreak. More 
comprehensive estimates of COVID-19 severity could help preparedness for the 
potential resurgence of a second wave. 
 
Other important quantities for healthcare system planning and modeling include 
the distribution of time intervals from symptom onset to seeking care, 
hospitalization, and death or discharge. Several studies have evaluated these 
time-to-event distributions early in the epidemic [15-19]; however these may 
have changed as the outbreak progressed.  
 
A seminal report on the epidemiology of COVID-19 in China indicates that mild 
cases have a 5.1% probability of death, and this probability increases markedly 
with severity [22]. However, to our knowledge, no study has evaluated CFR 
stratified by clinical category upon hospital admission. This information is 
important for prioritization of patients upon hospital admission.  
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Here, we assessed CFR among laboratory-confirmed COVID-19 cases reported 
until mid-April 2020 in mainland China, stratified by clinical category and region. 
We also explored the risk factors associated with fatal outcomes, and the key 
time-to-event intervals in provinces outside Hubei.  
 
Methods 
Case definitions and surveillance  
The National Health Commission of China (NHC) and the Chinese Center for 
Disease Control and Prevention (China CDC) launched a surveillance system to 
record information on COVID-19 cases in late December 2019 (See [23] for 
details). As the epidemic evolved, a total of seven versions of case definitions 
were issued by NHC [5, 15]. 
 
Four clinical categories of laboratory-confirmed COVID-19 patients have been 
identified by NHC, including mild-, moderate-, severe-, and critical-patients [23-
25]. Mild patients, introduced in the fifth and sixth versions of the COVID-19 case 
definition, refer to patients with no radiographic evidence of pneumonia. 
Moderate patients, introduced in the fourth version of the case definition, refers 
to patients with fever, respiratory symptoms, and radiographic evidence of 
pneumonia. Severe patients, introduced in the second version, refers to patients 
with either breathing problems, low finger oxygen saturation, low PaO2/FiO2 
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(PaO2 denotes partial pressure of oxygen in arterial blood; FiO2 denotes fraction 
of inspired oxygen), or pulmonary imaging having obvious progress of lesions 
(>50%) within 24~48 hours. Critical patients denote patients having any 
respiratory failure or shock, and any other organ failure that requires ICU 
admission. This definition was used from the very beginning of the outbreak. 
 
Patients were discharged when they met all the following criteria: 1) normal 
body temperature for more than 3 days, 2) significantly improved respiratory 
symptoms, 3) significantly relieved acute exudative lesions indicated by lung 
radiographic findings, and 4) negative nucleic acid detection by real-time RT-PCR 
using respiratory specimens on two consecutive days, with a sampling interval 
≥1 day [25].  
 
Data collection 
Daily aggregated data (hereafter referred to as the aggregated dataset) on the 
cumulative number of cases were extracted from the websites of national, 
provincial, and municipal Health Commissions [1]. Individual records on COVID-
19 cases (hereafter referred to as the individual dataset) were collected from 
two official publicly available sources from December 29, 2019 through to April 
17, 2020, including: 1) health authority websites [1]; 2) national and local 
government affiliated medias [26]. Individual information was extracted and 
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entered into a structured database comprising demographic characteristics, 
dates of symptom onset, first healthcare consultation, hospital admission, official 
announcement (reporting date), as well as outcome (i.e., death/discharge and 
corresponding dates). Each individual record was extracted and entered by three 
coauthors and was cross-checked to ensure data accuracy. Conflicting 
information was resolved based on the Health Commission data. Details on data 
collection, completeness, and censoring are provided in Appendix, Tables S1-2.  
 
Statistical analysis 
Using individual dataset, we analyzed demogr phic characteristics, risk factors 
associated with fatal outcome, and key time-to-event intervals to the provinces 
outside Hubei, where the majority of individual records were obtained (80.8%, 
11,793/14,590). We implemented a multivariate logistic regression model to 
explore the risk factors associated with death. We included age, sex, economic 
region [27], time interval from symptom onset to first medical consultation, first 
hospital admission, and laboratory diagnosis. We categorized China into three 
economic regions (see Appendix, Figure S1) [27].  
 
To estimate the key time-to-event intervals, including symptom onset to first 
healthcare consultation, hospital admission, laboratory diagnosis, and death or 
discharge, and from hospital admission to death or discharge, we fitted three 
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parametric distributions (Weibull, gamma, and lognormal) to empirical data 
using maximum-likelihood estimation. We selected the best fit based on the 
Akaike information criterion.  
 
Using the aggregated dataset as of April 17, we applied two methods to estimate 
CFR. First, we calculated a crude CFR based on the cumulative number of deaths 
divided by the cumulative number of cases, ignoring the time-lag between 
symptoms onset and death [28]. In a second approach, we adjusted for delays 
between hospitalization and death to obtain more accurate estimates of CFR, 
using the method described by Garske et al. for pandemic influenza A/H1N1 in 
2009 [29]. This approach weights cases in the denominator of the CFR based on 
the distribution of the time interval from hospital admission to death. Recent 
cases have lower weights since their outcomes is unlikely to be observed 
(Appendix). This approach generates time-stamped CFR estimates using 
aggregated data.  
 
To estimate CFR by clinical category, we compiled the proportion of cases and 
deaths in each category and region from different reports [30-32]. We then 
applied these proportions to our aggregated datasets of cases and deaths using 
resampling approaches (Appendix). 
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Lastly, we assessed the impact of importations on the CFRs and key time-to-
event intervals in sensitivity analyses. As of April 17, all 1,566 international 
importations were reported in provinces outside Hubei and no death has been 
reported among imported cases. Statistical analyses were performed in R 
(version 3.6.0).  
 
Ethics 
The study was approved by the Institutional review board from School of Public 
Health, Fudan University (IRB#2020-02-0802). All data were collected from 
publicly available sources and did not contain any personal information. 
 
Results 
As of April 17, 2020, a total of 82,719 laboratory-confirmed cases including 4,632 
deaths, 77,029 discharged and 1,058 patients who were still hospitalized were 
reported in mainland China (see Table S2 for details of each province). Of these, 
provinces outside Hubei accounted for 14,591 (17.6%, 14,591/82,719) of 
laboratory-confirmed cases, including 120 deaths (2.6%, 120/4,632), 13,535 
(17.6%, 13,535/77,029) discharged cases and 936 (88.5%, 936/1,058) patients 
who were still hospitalized. We collected individual information from publicly 
available official sources on 11,793 laboratory-confirmed cases detected outside 
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Hubei, accounting for 80.8% (11,793/14,590) of total cases reported, 65.0% 
(78/120) of deceased patients, and 27.7% (3,746/13,533) of recovered patients. 
Of the 11,793 cases, unresolved patients accounted for 67.6% (7,969/11,793) 
(Table 1). See Figure S3 for an epidemic curve of cases with available individual 
information.  
 
The median age of cases outside Hubei was 45 years (range, four days-97 years), 
and 53% (5,950/11,321) were male. Those who died were significantly older 
than those who were discharged (median age: 75 vs 42 years, p<0.001). 77% 
(59/77) of deaths occurred in adults aged 65 years or above, and 60% (47/78) 
were male. (Table 1)  
 
The intervals from symptom onset to first healthcare consultation, from 
symptom onset to hospitalization, and from symptom onset to laboratory 
confirmation were consistently longer for deceased patients than for those who 
recovered. However, disease progression was quicker in individuals who died: 
overall, the time interval from symptom onset to death was estimated to be 13.9 
days (95%CI: 1.9-47.2), and the interval from symptom onset to discharge was 
20.6 days (95%CI: 8.9-39.8). (Table 2)  
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Based on the total patients reported to the surveillance system, the CFR 
estimated by Garske’s method [29] was somewhat higher than crude CFR 
estimates (Table 3). CFR was 5.65% (95%CI: 5.50%-5.81%) for mainland China, 
with highest estimate in Wuhan (7.71%, 95%CI: 7.48%-7.94%), and lowest 
estimate in the provinces outside Hubei (0.86%, 95%CI: 0.72%-1.03%). 
 
In Wuhan, the CFR among critical patients was 86.49% (95%CI: 80.93%-
92.47%), which was 13-fold higher than that in provinces outside Hubei (6.07%, 
95%CI: 4.52%-7.72%). The CFR among critical patients was 6.6-fold higher than 
that of severe patients, 12.1-fold higher than that of moderate patients, and 41.2-
fold higher than that of mild patients. Smaller differences in mortality risk by 
clinical categories (0.8-10.3-fold) were observed in the rest of mainland China. 
(Figure 1) 
 
The CFR in provinces outside Hubei remained stable at around 1.0% after 
February 1, as estimated by Garske’s method [29]. In Wuhan, the CFR declined 
rapidly from 88.6% on January 28 to 8.5% on February 24, and remained stable 
afterwards. Similar patterns were observed in other regions, where the CFR 
became stable in late February (Figure 2). Multivariate logistic analysis revealed 
that increasing age and being male were risk factors for mortality (Table 4; see 
also Table S3 for univariate analysis).  
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The key time-to-event intervals were shorter for imported cases than that of 
domestic cases (Appendix, Figure S4). Excluding importations, the CFR in 
provinces outside Hubei provinces increased to 5.72% (95%CI: 5.57%-5.89%), 
while the CFR in mainland China increased to 0.93% (95%CI: 0.78%-1.11%). 
 
Discussion  
We have shown that the CFR was 5.65% in mainland China, with highest severity 
in Wuhan (7.71%) and lowest severity in provinces outside Hubei (0.86%). The 
CFR increased with clinical severity, which was estimated at 86.49% among 
critical patients in Wuhan, and 6.07% in provinces outside Hubei. Males and 
older patients were at increased risk of mortality. Both the time from symptom 
onset to outcome and from hospital admission to outcome was shorter for 
deceased patients than for those who recovered. These estimates account for 
delayed outcomes and recent updates in official statistics and could represent 
the most accurate estimates of COVID-19 severity in China so far.  
 
Our CFR estimate of 0.86% for COVID-19 patients outside Hubei province is 
higher than the crude CFRs reported by WHO and China CDC, which is 0.4-0.7% 
[22, 28]. This is expected as the crude CFR is an underestimate due to the 
inevitable delay between symptom onset and death. Another study of patients 
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outside Hubei which accounted for censoring reports an estimate comparable to 
ours (0.98%) [3, 5]. Our estimate for Wuhan is higher than in prior studies 
however (7.71% vs 5.91% [3, 5]), and this is likely explained by our adjustment 
for censoring and the addition of revised statistics on cases and deaths.  
 
Large variations in CFR were observed between countries [35]. Variations could 
be explained by difference in the sensitivity of surveillance systems to detect 
cases at different levels of the severity pyramid, differences in clinical care of 
severe and critical patients, and age structure and underlying conditions of the 
population. Accordingly, settings with limited health services like Iran, report a 
larger ratio of deaths to cases than other countries [36]. 
 
No specialized treatment for COVID-19 patients has been identified, and the 
mainstay clinical management has been supportive care. For non-critically ill 
patients, close follow-up is likely to be sufficient to manage the disease. But 
critically ill patients are more likely to develop ARDS and require ICU admission 
[37]. This likely explains our findings that critical patients have a higher fatality 
risk. The fatality risk in Wuhan and in the broader Hubei province was higher 
than in the rest of China, probably due to shortage of health services, and 
possible difficulties in keeping record of all cases in Wuhan. There was particular 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa578/5837356 by guest on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
16 
 
shortage of advanced health care facilities for critically ill patients, such as 
extracorporeal membrane oxygenation.  
 
As the domestic epidemic of COVID-19 was gradually brought under control in 
mainland China, the government implemented strict quarantine of international 
arrivals to prevent reintroductions. Care seeking delays were much shortened 
among international travelers due to enhanced monitoring and quarantine, 
possibly explaining the absence of fatal outcomes among imported COVID-19 
cases thus far. Reassuringly, due to the small number of imported cases relative 
to the domestic epidemic, our CFR estimates were not influenced by inclusion or 
exclusion of this subpopulation. 
 
Our findings reveal that older individuals and male patients experience higher 
fatality risk, which is consistent with a seminal report [22, 38]. Additionally, 
patients with underlying conditions had much higher fatality rates [22, 38]. Our 
study was unable to address the relative risk of fatal outcome among patients 
with underlying diseases compared to healthy people, because limited 
information was available from publicly available data sources.  
 
Our CFR estimates outside Hubei province indicate that the severity of SARS-
CoV-2 is lower than that of other diseases caused by zoonotic coronaviruses, 
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including Middle East respiratory syndrome (MERS, CFR 34.4% [39]), and severe 
acute respiratory syndrome (SARS, CFR 7% in mainland China and11% globally 
[40]). In contrast, the CFR of COVID-19, particularly in the epicenter of Wuhan, is 
more severe than that of pandemic 2009 influenza A(H1N1) virus 
hospitalizations (CFR of 1.4% in Asia [41]). 
 
Outside Hubei, close contacts of laboratory-confirmed cases were kept in 
quarantine for 14 days. Local hospitals tested patients with respiratory 
symptoms, those with epidemiological links to Hubei province, or to other 
COVID-19 patients. Surprisingly, only a small number of mild cases were 
captured. In our aggregated dataset for Guangdong province for instance, only 
8.2% of reported cases were mild, while the majority (80.1%) had moderate 
disease severity with presence of pneumonia. Chest x-ray confirmed pneumonia 
is a threshold for hospital admission in China, and thus our CFR estimates could 
approximately represent the fatality risk among hospitalized cases. Thresholds 
for hospitalization may vary among countries due to different clinical practices 
and health service capacity. 
 
Notably, the definition of suspected cases eligible for laboratory testing was 
broadened on January 27 to include milder patients. This would bias our sample 
towards more clinically severe cases before January 27, as reflected by the very 
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high CRF estimate before that date (89%). In addition to improvement in 
therapeutic capacity, the shift in surveillance definition could partially explain 
the declining trend of CFR in February and beyond. A robust estimate of CFR can 
be obtained after February 23 since 90% of deaths occurred within 26 days of 
hospitalization; these later estimates should be considered most trustworthy.  
 
Our study has some limitations. First, reliable individual records were retrieved 
from publicly available official sources; however records were scarce for Hubei 
because this province did not release complete individual information. And thus, 
we were unable to estimate key time-to-event intervals in Hubei using 
maximum-likelihood estimation.  
 
Second, to estimate the CFR stratified by clinical category in provinces outside 
Hubei, the proportions of patients in each clinical category was obtained from 
Guangdong data[32]. Geographically comprehensive information was not 
available. However, the proportion of severe and critical cases was similar in 
Guangdong province and provinces outside Hubei (10.9% vs. 11.3%), supporting 
the representativeness of our data. 
 
Third, assessment of clinical severity in Hubei, especially in the epicenter of the 
outbreak in Wuhan, is challenging because disease severity may be increased by 
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bottlenecks in local healthcare capacity. Complete and accurate documentation 
of causes of death during such a large outbreak is challenging. To correct for late 
reporting, omissions and mis-reporting of COVID-19 cases during the outbreak, 
Wuhan Authorities conducted a comprehensive and systematic verification 
between late March and middle April, adding a substantial amount of cases and 
deaths. We cannot rule out however the potential misclassification of COVID-19 
deaths. To the best of our knowledge, these data represent direct deaths from 
COVID-19 in otherwise healthy patients, as well as deaths among patients with 
comorbidities and a diagnosis of COVID-19. Even outside of a pandemic situation, 
ascertainment of cause of death is complicated; further analyses of vital statistics 
using excess mortality approaches will be important to resolve the direct and 
indirect contribution of COVID-19 to mortality.  
 
Conclusions 
In conclusion, our estimates of CFR among laboratory-confirmed cases suggest 
that COVID-19 is not as severe as SARS and MERS, but more severe than the 
pandemic 2009 H1N1 virus among hospitalized patients. The fatality risk of 
COVID-19 cases is higher in Wuhan, among male and in older ages. Our findings 
can inform the response to the on-going COVID-19 pandemic, provide useful 
parameters to model the effect of interventions on morbidity and mortality, and 
assist preparedness for a potential resurgence of the epidemic in China. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa578/5837356 by guest on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
20 
 
 
Contributors 
H.Y. conceived, designed and supervised the study. W.W., J.L., Y.C., H.Y., Y.Z., Q.Q., 
H.G., Xiang.W., L.W. and K.S. participated in data collection. X.D., J.Y., X.W., JX.Z., 
Z.C, J.Z., and Y.W. analyzed the data, and prepared the figures. J.Y. prepared the 
first draft of the manuscript. X.D., P.W., M.A., B.C., C.V., and H.Y. commented on the 
data and its interpretation, revised the content critically. All authors contributed 
to review and revision and approved the final manuscript as submitted and 
agree to be accountable for all aspects of the work. 
 
Acknowledgments  
We thank Xin Chen, Jiaxian Chen, and Sihong Zhao, from School of Public Health, 
Fudan University, and Yuheng Feng from School of Basic Medical, Sciences, 
Fudan University for providing assistance with data collection. 
 
Disclaimer: The findings and conclusions in this study are those of the authors 
and do not necessarily represent the official position of the National Institutes of 
Health or U.S. Department of Health and Human Services. 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa578/5837356 by guest on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
21 
 
Funding 
The study was supported by the grants from the National Science Fund for 
Distinguished Young Scholars (No. 81525023), National Science and Technology 
Major Project of China (No. 2018ZX10201001-010, No. 2018ZX10713001-007, 
No. 2017ZX10103009-005). 
 
Declaration of interests 
H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, 
Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche 
Pharmaceutical Company. BJC has received honoraria from Roche and Sanofi. 
None of those research funding is related to COVID-19. All other authors report 
no competing interests. 
 
 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa578/5837356 by guest on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
22 
 
Reference 
1. National Health Commission of the People’s Republic of China. Update on COVID-19 
as of 24:00 on April 17, 2020. Available at: 
http://www.nhc.gov.cn/xcs/yqtb/202004/5b4216ebda6f4d2a884ef6217f32c8fb.shtml. 
Accessed April 18, 2020. 
2. National Health Commission of the People’s Republic of China. Update on COVID-19 
as of 24:00 on April 14, 2020. 2020. 
http://www.nhc.gov.cn/xcs/yqtb/202004/35d096269e2848cdb4d3cb38e4c6bd1b.shtml 
(accessed April 15, 2020). 
3. National Health Commission of the People’s Republic of China. Notification on the 
correction of the number of confirmed and death cases of  COVID-19 in Wuhan. 
Available at: 
http://www.nhc.gov.cn/xcs/yqtb/202004/6f8eb06d959f4ab7b56fe03236920be1.shtml. 
Accessed April 18, 2020. 
4. Tian HY. an investigation of transmission control measures during the first 50 days of 
the COVID-19 epidemic in China. Science. 2020. 
5. Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity 
in China outside Hubei after control measures, and second-wave scenario planning: a 
modelling impact assessment. Lancet. April 8, 2020 (Epub ahead of print). 
6. Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-
novel Coronavirus (2019-nCoV): estimating the case fatality rate - a word of caution. 
Swiss Med Wkly 2020; 150: w20203. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa578/5837356 by guest on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
23 
 
7. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients 
Dying in Relation to COVID-19 in Italy. JAMA. Mar 23, 2020. (Epub ahead of print). 
8. Jung SM, Akhmetzhanov AR, Hayashi K, et al. Real-Time Estimation of the Risk of 
Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported 
Cases. Journal of clinical medicine 2020; 9(2). 
9. Mizumoto K, Chowell G. Estimating Risk for Death from 2019 Novel Coronavirus 
Disease, China, January-February 2020. Emerging infectious diseases 2020; 26(6). 
10. Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality 
ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak 
on the Diamond Princess cruise ship, February 2020. Euro Surveill 2020; 25(12). 
11. Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of 
COVID-19 in South Korea. Int J Infect Dis 2020; 93: 339-44. 
12. Wilson N, Kvalsvig A, Barnar  LT, Baker MG. Case-Fatality Risk Estimates for 
COVID-19 Calculated by Using a Lag Time for Fatality. Emerging infectious diseases 
2020; 26(6). 
13. Wu P, Hao X, Lau EHY, et al. Real-time tentative assessment of the epidemiological 
characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 
2020. Euro Surveill 2020; 25(3). 
14. WHO Collaborating Centre for Infectious Disease Modelling and Imperial College 
London. Report 4: Severity of 2019-novel coronavirus (nCoV). Available at: 
https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-
coronavirus/. Accessed February 25. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa578/5837356 by guest on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
24 
 
15. Zhang J, Litvinova M, Wang W, et al. Evolving epidemiology and transmission 
dynamics of novel coronavirus disease 2019 outside Hubei Province in China: a 
descriptive and modeling study. Lancet Infect Dis. April 2, 2020 (Epub ahead of print). 
16. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel 
Coronavirus–Infected Pneumonia. N Engl J Med 2020. 
17. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 
2019: a model-based analysis. Lancet Infect Dis. March 30, 2020 (Epub ahead of 
print). 
18. Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the 
transmission dynamics in Wuhan, China. Nat Med. March 19 2020 (Epub ahead of 
print). 
19. Yao Y, Tian Y, Zhou J, Ma X, Yang M, Wang S. Epidemiological characteristics of 
2019-ncoV infections in Shaanxi, China by February 8, 2020. Eur Respir J 2020. 
20. Wu P, Hao X, Lau EHY, et al. Real-time tentative assessment of the epidemiological 
characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 
2020. Euro Surveill 2020. 
21. WHO Collaborating Centre for Infectious Disease Modelling and Imperial College 
London. Dorigatti I, Okell L, Cori A, Imai N, Baguelin M, Bhatia S, et al. Report 4: 
Severity of 2019-novel coronavirus (nCoV). https://www.imperial.ac.uk/mrc-global-
infectious-disease-analysis/news--wuhan-coronavirus/. (accessed Feb 25 2020). 
22. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus 
Disease 2019 (COVID-19). Available at: 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa578/5837356 by guest on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
25 
 
https://www.chinadaily.com.cn/pdf/2020/who-china-joint-mission-on-covid-19-final-
report.pdf. Accessed March 19, 2020. 
23. Prevention. CCfDCa. Epidemic update and risk assessment of 2019 Novel 
Coronavirus. Available at: 
http://www.chinacdc.cn/yyrdgz/202001/P020200128523354919292.pdf. Accessed 
Jan 31. 
24. Nishiura H. Case fatality ratio of pandemic influenza. The Lancet Infectious diseases 
2010; 10(7): 443-4. 
25. Gérardin P, El Amrani R, Cyrille B, et al. Low clinical burden of 2009 pandemic 
influenza A (H1N1) infection during pregnancy on the island of La Réunion. PloS one 
2010; 5(5): e10896. 
26. The Paper. Update on COVID-19. Available at: 
https://www.thepaper.cn/newsDetail_forward_7027744. Accessed April 18, 2020. 
27. Penttinen PM, Kaasik-Aaslav K, Friaux A, et al. Taking stock of the first 133 MERS 
coronavirus cases globally--Is the epidemic changing? Euro Surveill 2013; 18(39). 
28. Wang W, Huang Y, Zhou WX, et al. [An outbreak of SARS in Dongcheng District, 
Beijing during March to June 2003]. Zhongguo yi xue ke xue yuan xue bao Acta 
Academiae Medicinae Sinicae 2003; 25(5): 533-8. 
29. Garske T, Legrand J, Donnelly CA, et al. Assessing the severity of the novel influenza 
A/H1N1 pandemic. BMJ 2009; 339: b2840. 
30. WHO-China Joint Mission. Report of the WHO-China Joint Mission on Coronavirus 
Disease 2019 (COVID-19). Available at: 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa578/5837356 by guest on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
26 
 
https://www.chinadaily.com.cn/pdf/2020/who-china-joint-mission-on-covid-19-final-
report.pdf. Accessed March 19. 
31. Wuhan Municipal Health Commission. Daily report on epidemic situation of COVID-
19 in Wuhan. (In Chinese). Available at: http://wjw.wuhan.gov.cn/ztzl_28/fk/tzgg/. 
Accessed May 8. 
32. Health Commission of Guangdong Province. Daily report on epidemic situation of 
COVID-19 in Guangdong province. (In Chinese). Available at: 
http://wsjkw.gd.gov.cn/zwyw_yqxx/index.html. Accessed May 8. 
33. Pan A, Liu L, Wang C, et al. Evolving epidemiology and impact of non-pharmaceutical 
interventions on the COVID-19 outbreak in Wuhan, China: analysis of 32 583 
laboratory-confirmed cases. JAMA (under review). 
34. National Health Commission of the People’s Republic of China. Notification on the 
correction of the number of confirmed and death cases of  COVID-19 in Wuhan. 
http://www.nhc.gov.cn/xcs/yqtb/202004/6f8eb06d959f4ab7b56fe03236920be1.shtml.  
Accessed April 18, 2020. 
35. Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of 
the COVID-19 case fatality rate. Lancet Infect Dis 2020. 
36. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 
343 2020. https://www.who.int/docs/default-source/coronaviruse/situation-
reports/20200303-sitrep-43-covid-19.pdf?sfvrsn=2c21c09c_2 (accessed March 4 
2020). 
37. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa578/5837356 by guest on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
27 
 
SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, 
observational study. Lancet Respir Med 2020: S2213-600(20)30079-5. 
38. Staikowsky F, D'Andréa C, Filleul L, et al. [Outbreak of influenza pandemic virus 
A(H1N1) 2009 infections in Emergency Department, Saint-Pierre, Reunion Island. 
July-August 2009]. Presse medicale (Paris, France : 1983) 2010; 39(7-8): e147-57. 
39. Liu W, Han XN, Tang F, et al. No evidence of over-reporting of SARS in mainland 
China. Tropical medicine & international health : TM & IH 2009; 14 Suppl 1: 46-51. 
40. Hsieh YH, King CC, Chen CW, Ho MS, Hsu SB, Wu YC. Impact of quarantine on the 
2003 SARS outbreak: a retrospective modeling study. Journal of theoretical biology 
2007; 244(4): 729-36. 
41. Wong JY, Kelly H, Cheung C-MM, et al. Hospitalization Fatality Risk of Influenza 
A(H1N1)pdm09: A Systematic Review and Meta-Analysis. Am J Epidemiol 2015; 
182(4): 294-301. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa578/5837356 by guest on 19 M
ay 2020
Ac
ce
pte
d M
an
us
cri
pt
 
28 
 
Table 1. Demographical characteristics of COVID-19 cases outside Hubei 
province in mainland China, as of April 3, 2020 
Characteristic 
Died  
(n=78) 
Discharged 
(n=3,746) 
Unresolved 
(n=7,969) a 
All cases 
(n=11,793) 
Median age (year, range) 75 (25-94) 42 (0.13-97) 46 (0.01-96) 45 (0.01-97) 
Age group (year) (n, %) b 
    
0-6 0 (0) 85 (2) 84 (1) 169 (2) 
7-17 0 (0) 129 (4) 200 (3) 329 (3) 
18-24 0 (0) 257 (7) 455 (6) 712 (7) 
25-49 4 (5) 1865 (52) 3565 (50) 5434 (50) 
50-64 14 (18) 877 (24) 1931 (27) 2822 (26) 
≥65 59 (77) 407 (11) 893 (13) 1359 (13) 
Missing c 1 (1) 126 (3) 841 (11) 968 (8) 
Sex (n, %) 
    
Male 47 (60) 1969 (53) 3934 (52) 5950 (53) 
Female 31 (40) 1727 (47) 3613 (48) 5371 (47) 
Missing c 0 (0) 50 (1) 422 (5) 472 (4) 
Region (n, %) d  
    
East 31 (40) 1614 (43) 3351 (42) 4996 (42) 
Central 20 (26) 978 (26) 2914 (37) 3912 (33) 
West and Northeast 27 (35) 1154 (31) 1704 (21) 2885 (24) 
 
a Including these cases who may had outcomes (i.e., death/discharge), but their information unavailable 
from public data sources. b Significant difference was observed among patients who died and the discharged 
(p<0.001). c: The denominator for estimating the proportion of missing data is the total number of COVID-
19 cases. Missing data were excluded for calculating the proportion per strata. d Significant difference was 
observed among patients who died and the discharged (p<0.05). East: Beijing, Tianjin, Hebei, Shanghai, 
Jiangsu, Zhejiang, Fujian, Shandong, Guangdong and Hainan provinces; Central: Shanxi, Anhui, Jiangxi, 
Henan, and Hunan provinces; West: Inner Mongolia, Guangxi, Chongqing, Sichuan, Guizhou, Yunnan, Tibet, 
Shaanxi, Gansu, Qinghai, Ningxia and Xinjiang; Northeast: Heilongjiang, Jilin and Liaoning. 
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Table 2. Key time to event intervals of COVID-19 patients outside Hubei province 
in mainland China, as of April 3, 2020 (mean, 95%CI) 
 
Key time-to-event interval 
All  
(n=11,793) 
Died 
(n=78) 
Discharged 
(n=3,746) 
Time from symptom onset to first 
healthcare consultation (days) 
n=3,804 n=36 n=1,360 
  Estimates from empirical data 1.0 (0.5, 10.2) 2.0 (0.5, 9.6) 1.0 (0.5, 10.0) 
  Estimates by fitting 1.6 (0.2, 12.4) 1.7 (0.2, 15.6) 1.5 (0.2, 12.1) 
Time from symptom onset to 
hospital admission (days) 
n=3,381 n=39 n=1,563 
  Estimates from empirical data 3.0 (0.5, 13.0) 4.0 (0.5, 12.5) 3.0 (0.5, 13.0) 
  Estimates by fitting 2.2 (0.3, 19.0) 3.5 (0.2, 16.0) 2.9 (0.2, 13.4) 
Time from symptom onset to 
laboratory confirmation (days) 
n=6,406 n=41 n=1,890 
  Estimates from empirical data 5.0 (0.5, 16.0) 6.0 (1.0, 14.8) 5.0 (0.5, 15.0) 
  Estimates by fitting 5.0 (0.5, 15.9) 5.8 (0.8, 15.8) 4.9 (0.5, 15.5) 
Time from symptom onset to 
outcome (days) 
n=2,178 n=46 n=2,132 
  Estimates from empirical data 20.0 (9.0, 42.0) 13.5 (3.1, 43.8) 20.0 (10.0, 42) 
  Estimates by fitting 20.4 (8.5, 40.3) 13.9 (1.9, 47.2) 20.6 (8.9, 39.8) 
Time from hospital admission to 
outcome (days) 
n=2,643 n=60 n=2,583 
  Estimates from empirical data 16.0 (6.0, 38.9) 9.0 (0.7, 37.5) 16.0 (7.0, 39.0) 
  Estimates by fitting 16.7 (5.8, 36.5) 9.3 (0.7, 39.1) 16.4 (7.0, 38.6) 
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Table 3. Fatality risk of COVID-19 among all reported cases, and among severe 
and critical cases a 
 
Number of cases  
Fatality risk among 
all reported cases  
(%, 95%CI) 
Death Total cases reported  Crude 
Estimated 
using 
Garske’s 
method 
[29]  
Wuhan in Hubei province 3,869 50,333  
7.69 
(7.46, 
7.92) 
7.71 
(7.48, 7.94) 
Outside Wuhan in Hubei province 643 17,795  
3.61 
(3.35, 
3.90) 
3.62 
(3.35, 3.90) 
Provinces outside Hubei  120 14,591  
0.82 
(0.69, 
0.99) 
0.86 
(0.72, 1.03) 
Overall 4,632 82,719  
5.60 
(5.44, 
5.76) 
5.65 
(5.50, 5.81) 
a crude fatality risk was calculated as the cumulative number of deaths divided by the 
cumulative number of laboratory-confirmed cases.  
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Table 4. Risk factors associated with fatal outcome among COVID-19 patients 
Variables OR (95%CI) Z-
value 
P-
value 
Age, per year increase 1.14 (1.11-
1.16) 
12.12 <0.001 
Sex    
Female ref / / 
Male 1.83 (1.10-
3.04) 
2.32 0.020 
Unknown 0 (0-Inf) -0.02 0.983 
Economic regions a    
East ref / / 
Central 1.41 (0.74-
2.70) 
1.05 0.294 
West and Northeast 1.38 (0.78-
2.46) 
1.10 0.271 
Time from symptom onset to first healthcare 
consultation 
   
  ≤2 days ref / / 
>2 days 1.27 (0.55-
2.90) 
0.56 0.577 
Unknown 0.47 (0.21-
1.05) 
-1.84 0.065 
Time from symptom onset to hospital admission    
≤3 days ref / / 
>3 days 1.12 (0.47-
2.67) 
0.25 0.805 
Unknown 0.64 (0.27-
1.51) 
-1.02 0.307 
Time from symptom onset to laboratory confirmation    
<=6 days ref / / 
>6 days 1.30 (0.58-
2.90) 
0.63 0.527 
Unknown 2.79 (1.13-
6.90) 
2.22 0.027 
a East: Beijing, Tianjin, Hebei, Shanghai, Jiangsu, Zhejiang, Fujian, Shandong, Guangdong 
and Hainan provinces; Central: Shanxi, Anhui, Jiangxi, Henan, and Hunan provinces; 
West: Inner Mongolia, Guangxi, Chongqing, Sichuan, Guizhou, Yunnan, Tibet, Shaanxi, 
Gansu, Qinghai, Ningxia and Xinjiang; Northeast: Heilongjiang, Jilin and Liaoning. /not 
applicable. 
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Figure legend 
Figure 1. Case-fatality risk (mean) by clinical categories (mild, moderate, severe 
and critical patients) (mean, 95%CI). 
 
Figure 2. Case-fatality risk over time in mainland China (%) (mean, 95%CI). 
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Figure 1 
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Figure 2 
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